EUVIMEDEUVIMED entdecken
Crossref

Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma

Chinmayee Goda, Sofia Kolovich, Alexander Rudich, Malith Karunasiri, Rohan Kulkarni, Girish Rajgolikar, Lotus Neidemire-Colley, Satishkumar Singh, Anuvrat Sircar, Parvathi Ranganathan, Ramiro Garzon, Lalit Sehgal und 1 weitere

Experimental Hematology · 2023

DOI: 10.1016/j.exphem.2023.05.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Hematology, 2023. Verfasst von Chinmayee Goda und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University Comprehensive Cancer Center, Columbus, OH. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is an aggressive, noncurative, mature B-cell lymphoma, with a median overall survival of 6-7 years. This underlines a need for effective therapeutic strategies to treat MCL better. Epidermal growth factor-like 7 (EGFL7) is a protein secreted by endothelial cells shown to play a critical role in angiogenesis. Our laboratory has previously demonstrated that EGFL7 supports the growth of leukemic blasts in patients with acute myeloid leukemia (AML); however, its role in MCL has not been investigated yet. In this study, we report that EGFL7 messenger RNA (mRNA) is increased in the cells of patients with MCL compared with cells from healthy controls, and patients with high EGFL7 are associated with lower overall survival rates. Furthermore, EGFL7 is increased in the plasma of patients with MCL compared with the plasma from healthy controls. We further show that EGFL7 binds to epidermal growth factor receptor (EGFR) and activates AKT signaling pathway in MCL cells and that blocking EGFL7 in MCL in patient and cell lines decreases cell growth and increases apoptosis in vitro. Finally, anti-EGFL7 treatment inhibits tumor size and prolongs survival in a mouse model of MCL. In conclusion, our study reveals a role for EGFL7 in MCL cell proliferation and highlights EGFL7 inhibition as a promising new treatment for patients with MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAnimalsMiceCell Line, TumorEGF Family of ProteinsEndothelial CellsSignal TransductionHumans

Substanzen

EGF Family of Proteins

Autor:innen und Institutionen

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • The Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address: Lalit.Sehgal@osumc.edu.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address: adrienne.dorrance@hci.utah.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Goda, C., Kolovich, S., Rudich, A., Karunasiri, M., Kulkarni, R., Rajgolikar, G., Neidemire-Colley, L., Singh, S., Sircar, A., Ranganathan, P., Garzon, R., Sehgal, L., & Dorrance, A. M. (2023). Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma. Experimental Hematology. https://doi.org/10.1016/j.exphem.2023.05.003

Vancouver

Goda C, Kolovich S, Rudich A, Karunasiri M, Kulkarni R, Rajgolikar G, et al. Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma. Experimental Hematology. 2023. doi:10.1016/j.exphem.2023.05.003

BibTeX
@article{Goda2023,
  author = {Goda, Chinmayee and Kolovich, Sofia and Rudich, Alexander and Karunasiri, Malith and Kulkarni, Rohan and Rajgolikar, Girish and Neidemire-Colley, Lotus and Singh, Satishkumar and Sircar, Anuvrat and Ranganathan, Parvathi and Garzon, Ramiro and Sehgal, Lalit and Dorrance, Adrienne M},
  title = {Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma},
  journal = {Experimental Hematology},
  year = {2023},
  doi = {10.1016/j.exphem.2023.05.003}
}
Kostenlos starten →